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Background: There as yet exists no systematic planning study investigating the novel mARC rotational
radiotherapy technique, which is conceptually different from VMAT. We therefore present a planning study for
prostate cancer, comparing mARC with IMRT treatment at the same linear accelerator equipped with flat and
flattening-filter-free (FFF) photon energies.
Methods: We retrospectively re-contoured and re-planned treatment plans for 10 consecutive prostate cancer
patients. Plans were created for a Siemens Artiste linear accelerator with flat 6 MV and FFF 7 MV photons, using
the Prowess Panther treatment planning system. mARC and IMRT plans were compared with each other
considering indices for plan quality and dose to organs at risk. All plans were exported to the machine and
irradiated while measuring scattered dose by thermoluminescent dosimeters placed on an anthropomorphic
phantom. Treatment times were also measured and compared.
Results: All plans were found acceptable for treatment. There was no marked preference for either technique or
energy from the point of view of target coverage and dose to organs at risk. Scattered dose was significantly
decreased by the use of FFF energies. While mARC and IMRT plans were of very similar overall quality, treatment
time could be markedly decreased both by the use of mARC and FFF energy.
Conclusions: Highly conformal treatment plans could be created both by the use of flat 6 MV and FFF 7 MV
energy, using IMRT or mARC. For all practical purposes, the FFF 7 MV energy and mARC plans are acceptable for
treatment, a combination of both allowing a drastic reduction in treatment time from over 5 minutes to about half
this value.
Keywords: mARC rotational treatment, Flattening-filter-free photons, Prostate cancer, Planning studyBackground
The mARC (“modulated arc”) technique has recently
been introduced as a rotational intensity-modulated ra-
diation therapy (IMRT) technique for Siemens linear ac-
celerators [1,2]. Although the dosimetric accuracy has
been assessed by various methods and first patient treat-
ment has been reported [3,4], no systematic planning
studies have yet been carried out to assess the quality of
mARC treatment as compared with IMRT delivered at
the same linear accelerator.
First applications have centered on prostate treatment
for mARC [4,5], which appears to be an ideal indication
as it benefits from inverse planning due to the proximity* Correspondence: yvonne.dzierma@uks.eu
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unless otherwise stated.of organs at risk (OAR), yet only requires one gantry ro-
tation to achieve a highly conformal dose distribution
(compare, e.g., [6]). We therefore present a planning
study for prostate cancer with mARC for a Siemens
Artiste machine equipped with flat 6 MV and flattening-
filter-free (FFF) 7 MV energies. The combination of FFF
beams with mARC treatment is of particular interest
since this offers the greatest potential for a reduction in
treatment time.
Although the mARC technique is a Siemens Artiste
specific modality and primarily interesting for Siemens
customers, we hope that the comparison of the flat and
FFF beam lines, both for mARC and IMRT treatment,
will be useful for a wide range of readers.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,











Posterior rectal wall D(max) <60 Gy
V50Gy <15%
V40Gy <30%
Femoral heads V50Gy <5%
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For the present study we chose 10 consecutive patients di-
agnosed with intermediate and high-grade prostate cancer
that had previously been treated in our department. Due
to the retrospective nature of this study, no ethics board
approval was required. Patient characteristics are shown
in Table 1. Computed tomography (CT) datasets had been
acquired on a dedicated scanner (Brilliance CT - Big Bore
Oncology, Philips, Koninklijke) with 3 mm spacing be-
tween slides. For all patients additional MRI data of the
small pelvis was present for coregistration. For reasons
of standardization contouring was completely redone by
one radiation oncologist according to the Radiation
Therapy Oncology Group (RTOG) Trial 0126 [7] con-
touring guidelines. Gross tumor volume (GTV), clinical
target volume (CTV), planning target volume (PTV)
and normal tissues were outlined on all CT slices in
which the structures existed.
The GTV encompassed the prostate gland, the CTV
encompassed the GTV plus the proximal bilateral sem-
inal vesicles (only the first 1.0 cm of the seminal vesicle
tissue adjacent to the prostate). The PTV was generated
by adding a surrounding margin of 7 mm to the CTV.
Organs at risk were outlined according to the Male
RTOG Normal Pelvis Atlas [8]. A dose of 76 Gy was
prescribed to the PTV, for plan evaluation we used our
in-house DVH (dose-volume histogram) criteria as
shown in Table 2 that are mainly based on the data pub-
lished by Quantitative Analysis Of Normal Tissue Effects
In The Clinic (QUANTEC) [9,10].
At our institution, the mARC technique is available at
one Siemens Artiste linear accelerator with flat 6 MV and
FFF 7 MV energy, equipped with 160 multi-leaf collimator
(MLC, leaf width 5 mm). The two energies are particularly
well suited for comparative planning as the slightly in-
creased nominal energy of the FFF 7 MV beam compen-
sates for the spectral softening caused by the removal of
the flattening filter, so that the percent depth dose of the
FFF 7 MV beam matches the flat 6 MV beam closely [11].Table 1 Patient characteristics
Mean Range






Gleason grading at diagnosis 7 6-9
PSA at diagnosis (ng/ml) 26.56 3.8-94
Anti androgen deprivation (yes/no) 10/0
Prostate volume (ccm) 61.6 39.55-91.22Therefore, any differences in plan quality will reflect mainly
the difference in beam profiles.
For mARC plans, one complete (360°) gantry rotation
was used with optimization points spaced 10° and arclet
length 4°. IMRT plans consisted of 11 beams (gantry an-
gles 205°, 235°, 265°, 295°, 330°, 0°, 30°, 65°, 95°, 125°,
155°), with 3 segments per beam. In a prior test, it was
checked if plans were improved by allowing 5 segments
per beam (the “gold standard” for prostate IMRT at our
institution). Since no significant difference was observed,
we here limit our analysis to IMRT plans with a total of 33
segments or less, which is nearly the same number of de-
grees of freedom as for the mARC plans (36 optimization
points). The collimator angle was 90° for all plans, also
based on previous tests.
Planning is performed in the Prowess Panther V5.10r2
treatment planning system (TPS) on a 3 mm dose grid
using the collapsed cone dose algorithm. IMRT and
mARC inversion are closely similar, both using a simu-
lated annealing approach for direct aperture optimization.
Based on a set of inversion objectives, the optimization
can be carried out interactively by adjusting the DVH con-
straints and weights until the desired shape is reached.
Criteria for optimization are listed in Table 2.
Plan quality was compared for the four scenarios (IMRT
vs. mARC, 6 MV vs. FFF 7 MV) based on the conformity
index (CI), the homogeneity index (HI), V(50Gy) for blad-
der and rectum, and V(40Gy) of the posterior rectal wall.




where TV denotes the volume of the PTV, PIV is the
volume enclosed in the prescribed isodose (95%), and
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scribed isodose (95%).
The homogeneity index is calculated as
HI ¼ DPTV 2%ð Þ−DPTV 98%ð Þ
DPTV 50%ð Þ
where DPTV(x %) means the dose received by x % of the
PTV volume.
All plans were exported to the machine for treatment
and irradiated on an Alderson anthropomorphic phan-
tom positioned with the prostate at the approximate lo-
cation of the isocenter. Thermo-luminescent dosimeters
(Harshaw TLD 100H) were placed at three positions on
the surface of the phantom (navel, manubrium sterni,
right eye lens) to measure the scattered dose outside the
treatment field. At each position, three TLDs were placed
in close proximity and the measurements averaged. The
average standard deviation of the three measurements was
below 5% for the measurements at the navel, and between
5 and 10% for the lower dose values measured at the ster-
num and lens. During irradiation, treatment times were
measured for comparison.
Plans were compared pair-wise for mARC vs. IMRT
and for 6 MV vs. 7 MV energy, considering the mea-
sures of quality defined above, monitor units, treatment
time and scattered dose. The Shapiro-Wilk test was per-
formed to check for normality. In cases where this could
not be refuted, the t-test for paired data was applied,
otherwise the Wilcoxon signed-rank test was used. A
value of p = 0.05 or below was considered to be statisti-
cally significant.Figure 1 Example dose distributions (transverse slices). The isodose lin
PTV is displayed as filled cyan contour.Results
All plans (DVH and dose distributions) were reviewed
by at least one senior radiotherapist and were all deemed
acceptable for treatment. All plans satisfied the criteria
that at least 95% of the planning target volume received
95% of the prescribed dose of 76 Gy, and all organs at
risk remained below the imposed limits (Table 2).
A visual comparison of the four plan scenarios for each
patient did not show a marked preference for either tech-
nique or energy (example dose distributions and DVH
shown in Figures 1 and 2). DVHs of the four scenarios are
closely similar for each patient. Relying on the quality mea-
sures (Table 3), the comparison of IMRT with mARC plans
for the same energy never yielded a significant difference.
For comparison of 6 MV with FFF 7 MV, homogeneity
index and conformity index were significantly better for 6
MV than 7 MV both for mARC and IMRT plans, separ-
ately. Considering dose to OAR, there was no significance
for comparison of IMRT plans (6 MV vs. 7 MV), but 6
MV mARC plans performed better than 7 MV mARC.
However, even in those cases where a statistical signifi-
cance was shown, the differences were very small and
hardly of clinical significance: For the bladder, a median of
20.8% of the volume received a dose of 50 Gy in the 6 MV
mARC plans, whereas this was 22.4% for 7 MV mARC.
The rectum V50 increases from 16.8% for 6 MV mARC to
17.5% for 7 MV mARC. As all these values remain far
below the allowed limits, they would not have caused rejec-
tion of the plans for clinical treatment. For all these values,
the variation between different patients was considerably
larger than the variation from one plan scenario to the
next, which can be seen by the overlapping ranges of
values (Table 3) even in cases where a small statistical
significance was found.es are given relative to the reference point, which receives 76 Gy. The
Table 3 Measures of quality, monitor units, treatment times and scattered dose for the four plan scenarios (median values ± standard deviation
(minimum-maximum), and p-values of pair-wise tests)












CI 0.896 ± 0.024 (0.855-0.945) 0.883 ± 0.014 (0.864-0.910) 0.909 ± 0.017 (0.878-0.925) 0.883 ± 0.024 (0.850-0.926) n.s. n.s. 0.029 0.004
HI 0.096 ± 0.010 (0.080-0.111) 0.100 ± 0.010 (0.093-0.122) 0.091 ± 0.011 (0.085-0.121) 0.102 ± 0.010 (0.088-0.126) n.s. n.s. 0.010 0.027
Bladder V50Gy (%) 21.0 ± 14.0 (6.3-48.7) 22.1 ± 14.1 (6.3-48.2) 20.8 ± 14.2 (6.0-49.3) 22.4 ± 14.6 (6.7-49.8) n.s. n.s. n.s. 0.004
Rectum V50Gy (%) 16.9 ± 5.1 (5.9-22.2) 17.2 ± 5.2 (7.1-23.7) 16.8 ± 5.2 (5.3-22.3) 17.5 ± 5.5 (5.7-23.4) n.s. n.s. n.s. 0.049
Post. Rect. Wall V40Gy (%) 3.8 ± 3.4 (0.0-9.7) 3.6 ± 4.2 (0.0-12.7) 3.5 ± 3.2 (0.0-8.3) 4.8 ± 4.2 (0.0-11.6) n.s. n.s. n.s. 0.043
MU 402 ± 29 (365–442) 402 ± 25 (368–445) 414 ± 29 (365–452) 411 ± 43 (366–507) 0.047 n.s. n.s. n.s.
Treatment time (min:sec) 5:21 ± 0:10 (5:09–5:40) 4:31 ± 0:04 (4:25–4:39) 3:35 ± 0:12 (3:20–3:55) 2:27 ± 0:09 (2:13–2:39) 0.002 0.002 0.002 0.002
Dose at navel (mGy) 15.5 ± 2.1 (12.8-18.8) 12.2 ± 1.7 (10.8-15.3) 14.6 ± 2.3 (12.7-19.0) 12.4 ± 2.2 (10.3-16.7) n.s. n.s. 0.002 0.002
Dose at manubrium (mGy) 1.47 ± 0.2 (1.21-1.86) 1.25 ± 0.2 (1.06-1.59) 1.52 ± 0.2 (1.33-1.87) 1.29 ± 0.2 (0.97-1.58) n.s. n.s. 0.002 0.002
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than the IMRT plans, but the difference was negligible
(not significant except for 6 MV IMRT vs. mARC, with
402 and 414 MU, respectively, p = 0.047). However,
treatment time could be markedly decreased both by the
use of mARC and FFF energy. In moving from 6 MV to
FFF 7 MV, about one minute treatment time was saved
both in IMRT and mARC, respectively. In moving from
IMRT (11 beams) to mARC, treatment times were re-
duced by about two minutes both for 6 MV and FFF 7
MV, respectively. By combining mARC treatment with
FFF 7 MV energy, the treatment time could effectively
be reduced by half (median 2:27 min for FFF mARC ver-
sus 5:21 min for 6 MV IMRT).
Scattered dose is significantly decreased by the use of
FFF energies, which is physically reasonable since head
scatter is reduced in the absence of a flattening filter.
For identical plan scenarios, the FFF 7 MV energy pro-
duces only about 58–85% of the scattered dose mea-
sured for flat 6 MV, with strongest reduction at larger
distance from the treatment field (lens). A difference be-
tween IMRT and mARC plans cannot be observed for 6
MV; for 7 MV, the out-of-field dose is slightly higher for
mARC (up to 108% of the 7 MV IMRT plan, but still
much lower than for the 6 MV plans).
Discussion
Monitor units
In this study, monitor units were not observed to differ
significantly between mARC and IMRT, and for 6 MV
vs. FFF 7 MV, respectively. This changes markedly if the
isocenter is displaced from the centre of the PTV. In this
case, the monitor units required by the 6 MV plans do
not change systematically – sometimes increasing, some-
times decreasing, but remaining within 30 MU of the
original value. For the FFF 7 MV plans, however, the
value increases strongly, sometimes exceeding 500 MU.
This is plausible, because if the isocenter moves to the
side or even outside of the PTV, the dose intensity de-
creases with distance from the central axis, creating a
constant dose gradient in the target. Additional monitor
units are hence required to add dose at greater distance
from the axis. This effect does not occur for the flat in-
tensity profile of the 6 MV beam. If the isocenter is
placed in the centre of the PTV, the dose profile of the
FFF 7 MV beam peaks inside the PTV and only deviates
from a flat profile at distances of several centimetres
from the axis. It appears that the prostate PTV is suffi-
ciently small to exhibit no notable difference in monitor
units between 6 MV and 7 MV plans if the isocenter is
centrally placed. If the PTV extended farther in the cra-
niocaudal direction, it might be expected that the dose
fall-off to the sides of the central axis – although symmet-
rical – would also require more monitor units for the FFFbeam: this was indeed observed for large PTV [13,14].
Therefore, the position of the isocenter is more critical for
the FFF energies.
Treatment times
Treatment times depend on the time for gantry and
MLC movement on the one hand and on the time re-
quired to irradiate the monitor units on the other hand.
As it is more time-consuming to stop the gantry at pre-
cise angles rather than just move it through an angular
range, mARC saves treatment time in comparison with
step-and-shoot plans that would use the same number
of gantry angles (i.e., 36 with one segment per beam).
The use of FFF beam energies saves time as the higher
dose rate allows faster irradiation of the ca. 400 MU.
We therefore assess the dependence of treatment time
on the number of MU for the four scenarios (Figure 3).
In all cases, a linear fit can be made, with parameters
given in Table 4. Based on the above considerations, the
y-axis intercept should be the same for both IMRT
plans and for both mARC plans, respectively, since it is
mainly determined by the irradiation geometry. The
slope of the curves should be similar for the 6 MV plans
and the 7 MV plans, respectively, since it depends on
the available dose rate.
Indeed, the y-axis intercepts of the IMRT plans for dif-
ferent energies differ less than one standard error; the
same applies to the mARC plans. The slope of the curves
for 6 MV plans also agree within less than one standard
error, with an approximate value of 0.27 s/MU – this cor-
responds to an average dose rate of 219 MU/min. For the
7 MV plans, the slope (again within less than one standard
error) of ca. 0.122 s/MU corresponds to an average dose
rate of 492 MU/min. These values are reasonable – the
maximum available dose rate for 6 MV is 300 MU/min.
For FFF 7 MV, 2000 MU/min are theoretically available.
However, for small segments/arclets with low MU, the
linac firmware automatically reduces the dose rate for bet-
ter linearity (for about 400 MU distributed over 33 seg-
ments or 36 arclets, the linac will nearly always operate at
a reduced dose rate since most segments receive only
about 10 MU). We therefore find that both the FFF IMRT
and mARC plans operate at an average dose rate consider-
ably below the maximum available; but still about twice as
fast as the flat energy.
Considering the treatment time, the question arises
what the technical limit for the mARC operation may
be. Given the results above, it might be imagined that
treatment times could be further improved if the plans
were irradiated with the maximum available dose rates
(300 MU/min for 6 MV and 2000 MU/min for FFF 7
MV). In addition, the spacing of optimization points and
distance of MLC leaf travel between successive arclets will
influence treatment time. Current work at our institution
Figure 2 Example dose-volume histogram (same patient as in Figure 1).
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irradiation, and the technical constraints imposed on
treatment time (Dzierma et al., in prep.). From the
technical/legal point of view, gantry rotation is re-
strained to be no faster than 360° per minute, but only
plan scenarios with hardly any MLC movement and
few monitor units per arclet appear to be capable of
achieving this speed. Future work will show where the
practical limits for treatment times are, and treatment
planning systems will then be evaluated by how closely
they can approach this technical limit.Comparison with other studies
Only few studies have investigated the plan properties
and treatment times associated with mARC planning
[1,4,5]. Their observed treatment times for prostate can-
cer are of the same order of magnitude as those reported
here, again for comparable plan qualities between mARC
and IMRT treatments.
Several past studies have evaluated plan quality for
VMAT/RapidArc treatment as compared with IMRTTable 4 Linear fit parameters for treatment time
vs. monitor units (Figure 2)
Plan y-axis intercept (s) Slope (s/MU)
Value Standard error Value Standard error
6 MV IMRT 216.7 30.5 0.263 0.076
7 MV IMRT 233.5 18.3 0.119 0.045
6 MV mARC 98.7 41.1 0.286 0.099
7 MV mARC 94.1 23.9 0.125 0.057(for an overview, see [15]). While details differ between
these studies – due on the one hand to variations in the
considered prostate PTV contours, and on the other
hand to different planning approaches – it was generally
found that VMAT treatment offers at least as good quality
plans as IMRT treatment, sometimes even with better spar-
ing of organs at risk. Depending on whether one or two
arcs were chosen for VMAT treatment and whether con-
stant or variable dose rate irradiation was allowed, plan
quality measures and OAR DVH values sometimes
favoured IMRT, sometimes VMAT treatment [16-24]; how-
ever, all studies observed a marked reduction in treatment
time by VMAT treatment, and generally a drastic reduction
in monitor units.
Our study explicitly created the scenarios in such a
way to offer approximately the same number of degrees
of freedom to both IMRT and mARC optimization pro-
cesses, which may explain the similar quality outcome.
Besides, it should be pointed out that the studies com-
paring VMAT with IMRT all relied on IMRT plans with
fewer fields – most chose 5 or 7 gantry angles for the
IMRT, so it can be expected that our IMRT plans with
11 beams might yield better plans, hence closing the gap
to rotational modulated treatment. Still, it has been ob-
served that the plan quality can be improved by including
more gantry angles even for the same number of segments
[25], which is not surprising since it offers more freedom
to the optimization from a geometrical point of view and
might allow for better mARC plan quality even with a simi-
lar number of free parameters for the optimization. How-
ever, it also appears plausible that this effect should saturate
for plans with many gantry angles – the more beams are
Figure 3 Treatment time as a function of monitor units for the ten patients, with linear fits. Fit parameters are given in Table 4.
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itional beam, with an optimum number of ca. 10–20 beams
depending on the target size [26]. In fact, our in-house
standards have evolved over the past few years from IMRT
plans with 5–7 beams to 11–13 beams for prostate cancer.
More beams are never used since they have not shown to
yield any further benefit, which may explain why the mARC
plan quality is not notably improved over the IMRT plans.
Considering the monitor units, we do not observe a
marked decrease for mARC vs. IMRT plans, whereas
most studies considering VMAT vs. IMRT treatment do.
The monitor units for the mARC plans are comparable
to those found by, e.g., [6,16,19-21,23,24,27] all of whom
except for Ost et al. [27] had considerably higher IMRT
monitor units. It cannot be decided whether the low
amount of MU also for IMRT is indebted to the plan-
ning scenario (more degrees of freedom offered by 11
beam angles) or the planning system (the direct aper-
ture optimization algorithm used in Prowess Panther
has been observed to require fewer MUs for IMRT in
comparison with other planning systems [28]). The low
number of monitor units for our IMRT plans also
entails relatively fast IMRT treatment (5:21 minutes for
flat and 4:31 minutes for FFF beams), which is at
the lower limit of what is observed in other studies
(4–6 min [6,17,19,20,22,23,27,29,30]; 8 min [21,31]).
mARC treatment times of 3:35 min for flat and 2:27 min
for FFF treatment plans are slower than times reported
for VMAT treatment with single arcs (1–2 minutes
[6,17,19-21,27]; FFF: 60–90 sec [14,30,32]), but within the
range of times found for two arcs (3–5 min [6,20,21,23]).Conclusion
Although small differences in plan quality exist, none of
these were found to be clinically significant. Highly con-
formal treatment plans could be created both by the use of
flat 6 MV and FFF 7 MV energy, using IMRT or mARC. For
all practical purposes, the FFF 7 MV energy and mARC
plans are acceptable for treatment, allowing a drastic reduc-
tion in treatment time from over 5 minutes to about half this
value. As expected on physical grounds and based on past
studies, scattered dose is reduced by the FFF 7 MV energy.
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